Could a Different Kind of Blood Test Improve Ovarian Cancer Screening?
A study found that a blood test measuring cancer-associated proteins detected signs of early-stage ovarian cancer in samples collected up to a year before diagnosis.
A study found that a blood test measuring cancer-associated proteins detected signs of early-stage ovarian cancer in samples collected up to a year before diagnosis.
Hologic has agreed to acquire Reveal Genomics, adding the HER2DX assay to its oncology diagnostics portfolio and expanding genomic testing options for breast cancer, according to a company statement.
Guardant Health will present 25 abstracts at ESMO 2026, highlighting new data on ctDNA liquid biopsy for cancer monitoring, including MRD surveillance and therapy resistance in lung, colorectal, and gastric cancers.New research examines how circulating tumor DNA testing could help detect cancer recurrence, track treatment response, and identify resistance across multiple cancer types.
The DNA-based test showed 96.8% specificity in cervical samples and could help physicians determine which patients need further testing for endometrial cancer.
Read MoreBiodesix presented data at CHEST 2026 from over 2,000 patients in the CLARIFY study, highlighting how Nodify Lung blood-based testing integrates with PET imaging to improve follow-up adherence for pulmonary nodules.
Read MoreAnalyzing the structure of existing biomarkers could reveal new information about cancer, helping laboratories deliver more accurate and clinically useful results.
Read MoreCastle Biosciences’ new data presented at ACG 2026 show the TissueCypher test offers objective risk stratification for Barrett’s esophagus progression, providing information beyond standard histopathology.
Read MoreIMS Solutions, a University of Birmingham and Imperial College London spin-out, has raised £1.1 million to commercialize mass spectrometry-based steroid biomarker tests for adrenal cancer and PMOS, with clinical validation underway.
Read MoreNew data show high diagnostic performance for ovarian, endometrial, and cervical cancers, with a targeted assay designed to run on existing clinical laboratory equipment.
Read MoreAn independent validation study of 426 patients evaluated the assay’s ability to assess 10-year recurrence risk and identify patients more likely to benefit from radiation therapy.
Read More10x Genomics and Fred Hutchinson Cancer Center have launched a multi-project collaboration to study single cell and spatial profiling for cancer diagnostics, including biomarkers in bladder cancer and residual disease detection in AML.
Read MoreCerenome has launched two CSF-based molecular profiling tests for CNS cancers, offering DNA and RNA sequencing panels to evaluate primary, metastatic, and hematologic malignancies in the central nervous system.
Read MorePillar Biosciences has introduced the oncoReveal Myeloid v2 Panel, expanding its NGS assay from 58 to 80 genes and enhancing FLT3-ITD detection while maintaining existing laboratory workflows.
Read MoreA study found that Quest Diagnostics’ Haystack MRD ctDNA test detected colorectal cancer recurrence with up to 100% specificity, outperforming CEA testing in DYNAMIC trial patient specimens.
Read MoreA Stanford-led study found that Resero Bio’s uRARE-seq urine cfRNA test can non-invasively detect bladder cancer, assess tumor grade, and predict therapy response in 683 patient samples.
Read MoreUsing microfluidic shear stress, the system detaches living cells from excised tissue to support pathology workflows and downstream diagnostic testing.
Read MoreAstrin Biosciences has expanded access to its Certitude breast cancer blood test to 48 states through OpenLoop Health. The assay showed 92% sensitivity and 93% specificity in clinical validation.
Read MoreProject HOPE, funded by The Labcorp Charitable Foundation, has launched a two-year Madison, Wisconsin, initiative with local clinics to expand PSA testing and prostate cancer care for uninsured men facing access barriers.
Read More